

Mat Soc Med. 2012 Jun; 24(2): 100-105

Received: 10 January 2012

Accepted: 15 March 2012

CONFLICT OF INTEREST: none declared.  
© AVICENA 2012

doi: 10.5455/msm.2012.24.100-105

# Asthma and Chronic Obstructive Pulmonary Disease (COPD) – Differences and Similarities

Vesna Cukic, Vladimir Lovre, Dejan Dragisic, Aida Ustamujic

Clinic for Pulmonary Diseases and TB “Podhrastovi”, Clinical center of Sarajevo University, Bosnia and Herzegovina

**Corresponding author:** Corresponding author: Vesna Cukic, MD. Clinic for Pulmonary Diseases and TB “Podhrastovi” KCU Sarajevo. Sarajevo, B&H. Tel.: +387 61 480 228. E-mail: v.cukic@hotmail.com

## PROFESSIONAL PAPER

### SUMMARY

Bronchial asthma and COPD (chronic obstructive pulmonary disease) are obstructive pulmonary diseases that affected millions of people all over the world. Asthma is a serious global health problem with an estimated 300 million affected individuals. COPD is one of the major causes of chronic morbidity and mortality and one of the major public health problems worldwide. COPD is the fourth leading cause of death in the world and further increases in its prevalence and mortality can be predicted. Although asthma and COPD have many similarities, they also have many differences. They are two different diseases with differences in etiology, symptoms, type of airway inflammation, inflammatory cells, mediators, consequences of inflammation, response to therapy, course. Some similarities in airway inflammation in severe asthma and COPD and good response to combined therapy in both of these diseases suggest that they have some similar pathophysiologic characteristics. The aim of this article is to show similarities and differences between these two diseases. Today asthma and COPD are not fully curable, not identified enough and not treated enough and the therapy is still developing. But in future better understanding of pathology, adequate identifying and treatment, may be and new drugs, will provide a much better quality of life, reduced morbidity and mortality of these patients.

**Key words:** asthma, COPD, differences, similarities.

## 1. INTRODUCTION

Bronchial asthma and COPD (Chronic Obstructive Pulmonary Disease) are obstructive pulmonary diseases that affected millions of people all over the world. These two illnesses have many similarities and many differences which may sometimes confuse therapists in the diagnostics and management of these diseases which affect more and more people every year worldwide.

Although asthma and COPD have many similarities, they also have many differences. COPD is not asthma. Asthma is not COPD. They have:

- Different etiology;
- Different symptoms;
- Different type of airway inflammation;
- Different inflammatory cells;
- Different mediators;
- Different consequences of inflammation;
- Different response to therapy;
- Different course.

## 2. ASTHMA

Asthma is a chronic inflammatory disorder of the airways (1). The chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly at night or in early morning (1, 2). These episodes are usually associated with widespread, but variable, airflow obstruction within lung that is often reversible either spontaneously or with the treatment (1).

Asthma is a serious global health problem with an estimated 300 million affected individuals (2, 3). People of all ages are affected by this illness that, when uncontrolled, can place severe limits on daily life and is sometimes fatal (1). The prevalence of asthma is increasing in most countries (3). Clinical manifestations of asthma can be controlled with appropriate treatment. When asthma is controlled severe exacerbations should be rare (1). The clinical spectrum of asthma is highly variable, but the airway inflammation remains a consistent feature (1).

Factors that influence the risk of asthma can be di-

vided into those that cause the development of asthma and those that trigger asthma symptoms; some do both. The first include host factors (which are primarily genetic) and second are usually environmental factors (4, 5, 6).

### Factors influencing the development and expression of asthma

#### Host Factors

Genetic, e.g.,

- Genes pre-disposing to atopy
- Genes pre-disposing to airway hyperresponsiveness

Obesity, Sex

#### Environmental factors

Allergens

- Indoor: domestic mites, furred animals ( dogs, cats, mice), cockroach allergen, fungi ,molds, yeasts,
- Outdoor: Pollens, fungi, molds, yeasts

Infections (predominantly viral)

Occupational sensitizers

Tobacco smoke (active smoking, passive smoking)

Outdoor/Indoor Air Pollution

Diet

### 2.1. Airway inflammation in asthma

The airway inflammation in asthma is persistent even though symptoms are episodic, and the relationship between the severity of asthma and the intensity of inflammation is not clearly established (1). The inflammation affects all airways including in most patients the upper respiratory tract and nose but its physiological effects are most pronounced in medium sized bronchi (1). The pattern of inflammation in the airways appears to be similar in all clinical form of asthma, whether allergic, non-allergic, or aspirin-induced and at all ages (1).

### 2.2. Inflammatory Cells in Asthmatic Airways

**Mast cells** -activated mucosal mast cells release bronchoconstrictor mediators—histamine, cysteinyl leukotriens, prostaglandin D<sub>2</sub>. They are activated by allergens through IgE receptors or by osmotic stimuli (7). **Eosinophils** are in increased number in airways, release basic proteins that may damage epithelial cells, and have a role in releasing a growth factors and airway remodeling (8), **T lymphocytes** are in increased number and release specific cytokines, including IL-4, IL-5, IL-9, IL-13 that orchestrate eosinophilic inflammation and IgE production by B lymphocytes (9). There may also be an increase in inKT cells which release large amounts of T helper: Th1 and Th2 cytokines (10, 11). **Dendritic cells, Macrophages** are in increased number, and release inflammatory mediators and cytokines that amplify the inflammatory response (12, 13). **Nutrophils** are in increased number in airways and sputum of patients with severe asthma and in smoking asthmatics, but the role of these cells is uncertain and their increase may even be due to steroid therapy (12, 13, 14).

### 2.3. Inflammatory Mediators Involved in Asthma

**Chemokines** are important in the recruitment of inflammatory cells into the airways and are mainly expressed in airway epithelial cells (15, 16, 17). Eotaxin is selective for eosinophils, whereas thymus and activation-regulated chemokines (TARC) and macrophage-derived chemokines (MDC) recruit Th2 cells (16, 17). **Cysteinyl leukotrienes** are potent bronchoconstrictors and proinflammatory mediators mainly derived from mast cells and eosinophils (18). **Cytokines** orchestrate the inflammatory response in asthma. Key cytokines include IL-1 $\beta$  and TNF $\alpha$ , and GM-CSF. Th2-derived cytokines include IL-5, which is required for eosinophil differentiation and survival; IL-4, which is important for Th2 cell differentiation; and IL-13, needed for IgE formation (19). **Histamine** is released from mast cells and contributes to bronchoconstriction and inflammation (15, 16). **Nitric oxide** (NO), a potent vasodilator, is produced from syntheses in airway epithelial cells (20). Exhaled NO is increasingly being used to monitor the effectiveness of asthma treatment (21). **Prostaglandin D<sub>2</sub>** is a bronchoconstrictor derived predominantly from mast cells and is involved in Th2 cell recruitment to the airways (7).

Airway structural cells involved in the pathogenesis of asthma are: airway epithelial cells, airway smooth muscle cells, endothelial cells, fibroblasts and myofibroblasts and airway nerves (13, 14, 22, 23).

## 3. COPD

COPD is one of the major causes of chronic morbidity and mortality worldwide. Many people suffer from this disease for years and die prematurely from its complications. COPD is the fourth leading cause of death in the world (24), and further increases in its prevalence and mortality can be predicted in the coming decades (25,26).

COPD is a pulmonary disease with some significant extrapulmonary effects that may contribute to the severity in individual patient. Its pulmonary component is characterized by airflow limitation that is not fully reversible (27). The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases (24).

COPD has variable natural history and not all individuals follow the same course. However COPD is generally a progressive disease, especially if a patient's exposure to noxious agents continues. The impact of COPD on an individual patient depends on the severity of symptoms (especially breathlessness and decreased exercise capacity, cough, mucous production), systemic effects, and any co-morbidity the patient may have -not just on the degree of airflow limitation (24, 27, 28). COPD is characterized by chronic airflow limitation and a range of pathological changes in the lung, some significant extra-pulmonary effects and important co-morbidities which may contribute to the severity of the disease in individual patient (27, 28). Systemic manifestations and co-morbidities in COPD are body weight loss, skeletal muscle wasting, cachexia, osteoporosis, pulmonary heart-cor pulmonale, heart failure, cardiac ischemia, cardiac arrhythmias, anemia, hypoalbuminemia, diabetes, cognitive deficits, depres-

sion (28,29) . Co-morbidities are common for people with COPD because organ systems work differently when they do not receive enough oxygen. Thus, COPD should be regarded as a pulmonary disease, but these significant co-morbidities must be taken into account in a diagnostic assessment of severity and in determining appropriate treatment (27, 28, 29). **Cigarette smoking** is the most commonly encountered risk factor for COPD, although in many countries, air pollution resulting from the burning of wood and other biomasses fuels has also been identified as a COPD risk factor (24, 27,30).

**3.1. Inflammatory Cells in COPD**

**Neutrophils** are present in sputum of smokers but increased in COPD and related to disease severity. They may be important in mucus hypersecretion and through release of proteases. **Macrophages:** big numbers are in airway lumen, lung parenchyma, and bronchoalveolar lavage fluid. They produce increased inflammatory mediators and proteases and may show defective phagocytosis. **T lymphocytes:** both CD4+ and CD8+ cells are increased in the airway wall and lung parenchyma, with big CD8+/CD4+ ratio. Increased is the number of CD8+ T cells (Tc1) and Th1 cells which secrete interferon-γ and express the chemokine receptor CXCR3. CD8+ cells may be cytotoxic to alveolar cells. **B lymphocytes:** are increased in peripheral airways and within lymphoid follicles, possibly as a response to colonization and infection. **Eosinophils:** increased eosinophil proteins in sputum and eosinophils in airway wall during exacerbations. **Epithelial cells:** May be activated by cigarette smoke to produce inflammatory mediators (31, 32, 33, 34,35 ,36).

**3.2. Inflammatory Mediators Involved in COPD**

**Chemotactic factors: Lipid mediators:** e.g., leukotriene B4 (LTB4) attracts neutrophils and T lymphocytes, **Chemokines:** e.g., interleukin-8 (IL-8) attracts neutrophils and monocytes. **Proinflammatory cytokines:** e.g., tumor necrosis factor- (TNF-α), IL-1 β, and IL-6 amplify the inflammatory process and may contribute to some of the systemic effects of COPD. **Growth factors:** e.g., transforming growth factor-β (TGF-β) may induce fibrosis in small airways (31, 32, 34, 37).

**3.3. Airflow limitation in COPD**

The chronic airflow limitation of COPD is caused by a mixture of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person (24). Chronic inflammation causes structural changes and narrowing of small airways. Destruction of the lung parenchyma, also by inflammatory processes, leads to the loss of alveolar attachments to the small airways and decreases lung elastic recoil; in turn these changes diminish the ability of the airways to remain open during expiration (32, 34, 35).

So in COPD inflammation causes small airway disease (airway inflammation, airway remodeling) and parenchymal destruction (loss of alveolar attachments and decrease of elastic recoil) that all lead to airflow

limitation (32,34,35)

**4. ASTHMA AND COPD**

COPD can coexist with asthma; both are characterized by an underlying airway inflammation. The underlying chronic airway inflammation is very different in these two diseases (32, 38) (Table 2). However, individuals with asthma who are exposed to noxious agents, particularly cigarette smoke may develop fixed airflow limitation and a mixture of “asthma -like” and “COPD-like” inflammation (38). Furthermore, there is epidemiologic evidence that longstanding asthma on its own can lead to fixed airflow limitation (38,39). Other patients with COPD

ASTHMA and COPD		
	ASTHMA	COPD
<b>Cause:</b>	sensitive agent	noxious agent (mainly cigarette smoking)
	<b>Asthmatic airway inflammation</b> (CD4+T-lymphocytes and Eosinophils )	<b>COPD airway inflammation</b> (CD8+T-lymphocytes, Macrophages and Neutrophils)
	Reversible	Not fully reversible
	<b>AIRFLOW LIMITATION</b>	

Table 1. Differences in cause, inflammation and airflow limitation between asthma and COPD

	COPD	ASTHMA	SEVERE ASTHMA
Cells	Neutrophils ++ Macrophages +++ CD8+T cells (Tc1) CD4+Tcells (Th2) Th17	Eosinophils ++ Macrophages + Mastocites CD4+Tcells (Th2)	Neutrophils + Macrophages CD4+Tcells (Th2) CD8+T cells(Tc1) Th17
Key mediators	IL- 8 TNFα,IL-1β,IL-6 NO+	Eotaxin IL-4,IL-5,IL-13, NO+++	IL-8 IL-5,IL-13 NO++
Oxidative stress	+++	+	+++
Site of disease	Peripheral airways Lung parenchyma Pulmonary vessels	Proximal airways	Proximal airways Peripheral airways
Consequences	Squamous metaplasia Mucous metaplasia, Small airway fibrosis Parenchymal destruction, Pulmonary vascular remodeling	Fragile epithelium Mucous metaplasia, ↑ Basement membrane, Bronchoconstriction	
Response to therapy	Small b/d response Poor response to steroids	Large b/d response Good response to steroids	Smaller b/d response Reduced response to steroids

Table 2 Differences in pulmonary inflammation between asthma and COPD. No. = nitric oxide, b/d = bronchodilator (revised table from GOLD 2006.)

may have features of asthma such as a mixed inflammatory pattern with increased eosinophils (31). Thus, while asthma can usually be distinguished from COPD, in some individuals with chronic respiratory symptoms and fixed airflow limitation it remains difficult to differentiate the two diseases.

There are differences between cause, airway inflammation and airflow limitation between asthma and COPD.

The primary differences in pulmonary inflammation between asthma and COPD are shown in Table 2.

Some basic differences between asthma and COPD are seen in Table 3.

	ASTHMA	COPD
<b>Atopy</b>	Usually with atopy	Without atopy
<b>Symptoms</b>	Variable wheezing	Persistent symptoms
<b>Beginning</b>	Usually child or young age	> 45 years
<b>Course</b>	Variable, remissions, Sometimes progressive	Progressive
<b>Smoking</b>	Sometimes	Usually
<b>Bronchial hyperreactivity (BHR)</b>	Expressive BHR	Minimal BHR
<b>Response to bronchodilators</b>	Good	Bad
<b>Response to corticosteroids</b>	Good	Bad

Table 3. Asthma versus COPD

Asthma and COPD are usually differentiated (Table 4):

- Different inflammatory cells
- Different inflammatory mediators
- Different response to therapy

Asthma and COPD are usually similar:

- “Reversible COPD” (asthma coexists)

ASTHMA		COPD
predominantly: mastocites eosinophils	expression of inflammatory genes	predominantly: macrophages neutrophils
Th2 cells		Th1 cells
<b>AIRWAY OBSTRUCTION</b>		
Steroid sensitive		Steroid resistant
B/d sensitive		B/d resistant

Table 4.. Airway inflammation

- Severe asthma
- Asthma in smokers
- Neutrophil asthma (asthma in smokers, non-allergic asthma)
- Acute exacerbation

	Mild ASTHMA	Severe ASTHMA	COPD
<b>Eosinophils</b>	+++	+	(+)
<b>Neutrophils</b>	-	++	+++
<b>T-lymphocytes</b>	Th2	Tc1, Th2, Th17	Tc1, Th2, Th17
<b>TNFα</b>	-	++	+++
<b>IL-8</b>	-	++	+++
<b>Oxidative stress</b>	+	+++	+++
<b>Response to steroids</b>	+++	+/-	-
<b>Severe asthma</b>			
Neutrophils +/- eosinophils, +++ oxidative stress, steroid resistance			
<b>Asthma in smokers</b>			
neutrophils +/- eosinophils, +++ oxidative stress, steroid resistance			
<b>Acute exacerbation</b>			
neutrophil +/- eosinoph, +++ oxidative stress, steroid resistance			

Table 5. Inflammatory cells included in airway inflammation in Asthma and COPD

Similarities in airway inflammation and obstruction

ASTHMA		COPD
Bronchoconstriction (Multiple mediators)		Small airway fibrosis
Mucous edema (acute exacerbation)		Emphysema
Mucous plugs		Mucous exudates
Structural changes (irreversible asthma)		Mucous edema (acute exacerbation)

Table 6 Airway obstruction in asthma and COPD

between asthma and COPD are shown on Table 4 and 5). Inflammatory cells are included in airway inflammation..

Causes of airway obstruction in asthma and COPD are different. There are some similarities and differences in pathological changes in airways in severe asthma and

SEVERE (fatal) ASTHMA		SEVERE COPD
+++	Inflammation	+++
+++	Smooth muscles (spasm)	+
+++	Basal membrane damage	-
+	Fibrosis	+++
-	Alveolar disruption	+++

Table 7. Severe (fatal) Asthma Severe COPD

COPD (Table 7).

Functional pulmonary testing (spirometry, body-plethysmography) is most important for diagnosis, determining of severity and management of both asthma and COPD. Characteristics of functional pulmonary testing

	ASTHMA	COPD
Flow	=/ -	-
BD response (>15%)	+	-/+
Variability	+	-
BHR	++	+
DLCO	+	-
Hyperinflation	0/+	+(++)
Lung elasticity	0	-

Table 8. Characteristics of functional pulmonary testing

are shown on Table 8.

There are differences in functional pulmonary testing between asthma and COPD, especially between “typical-reversible” asthma and COPD.

But pulmonary functional testing is very similar in fixed “non-reversible” progressive asthma and COPD (1, 24, 31, 32,38, 39)

#### 4.1. Similarities and differences in acute exacerbation of asthma and COPD

- Pathology is different in exacerbation of asthma and COPD
- Causes of acute exacerbation of asthma and

- COPD are different.
- Different role of LABA ( long-acting  $\beta$ -2 agonists) and ICS (inhalatory corticosteroids) in prophylaxis of exacerbation of asthma and COPD.
- Treatment of acute exacerbation is similar in asthma and COPD.

**Acute exacerbation of Asthma**

Triggers of acute exacerbation of asthma are usually: allergens, infections (respiratory viruses, sometimes bacterial infections), GE (gastro-esophageal) reflux, other triggers, sometimes and co-morbidity (1, 4, 5, 6).

Pharmacotherapy of acute asthma exacerbation

- (inhalatory) Bronchodilators (A);
- $\beta$ -2 agonists and/or anticholinergics;
- (systemic /oral) corticosteroids (A).

Other therapy

- oxygen therapy (A);
- metilxantins (B);
- non -invasive mechanical ventilation (A);
- antibiotics;
- epinephrine (adrenalin) –rarely in a very serious asthma attack;
- He/Ox(helium/oxygen inhalation) rarely and MgSO4 intravenously rarely.

**Acute exacerbation of COPD**

**Triggers of acute exacerbation of COPD are usually:** infections (respiratory viruses, bacterial infections), air-pollution, GE (gastro –esophageal) reflux, sometimes and co-morbidity (24, 30).

**Pharmacotherapy of acute COPD exacerbation:**

- (inhalatory) Bronchodilators (A);
- $\beta$ -2 agonists and/or anticholinergics;
- (systemic /oral) corticosteroids (A);
- antibiotics in patients with severe exacerbation (b)

Other therapy:

- oxygen therapy (A);
- metilxantins (B);
- non -invasive mechanical ventilation (A).

**4.2. Similarities and differences in regular standard treatment of asthma and copd**

- In both diseases the adequate treatment may reduce symptoms and number of exacerbations and improve the quality of life.
- Treatment of asthma is characterized by suppression of inflammation.
- Treatment of COPD is characterized by decreasing of symptoms.

**The GOAL of treatment in ASTHMA is to:** reduce inflammation and to achieve, total control (1). **The GOAL of treatment in COPD is to:** reduce symptoms, prevent exacerbations and decrease mortality (24). In both asthma and COPD almost the same drugs are used, but not in the same order and the same efficiency in treatment.

**In Asthma, ICS** (inhalatory corticosteroids), decrease number of exacerbations, improve pulmonary function for long time , slow the decreasing of pulmonary function, decrease re-modulation of airways and reduce needs for additional medications (1, 43-48). **In COPD, ICS** are useful in patients with COPD with bigger degree of

ASTHMA	COPD
<u>Anti-inflammatory drugs</u>	<u>Bronchodilators</u>
Corticosteroids	$\beta$ -2 agonists
Antileucotriens	Anticholinergics
Cromones	Theophylins
(rarely in mild asthma)	
Theophylins (?)	
<u>Bronchodilators</u>	<u>Anti-inflammatory drugs</u>
$\beta$ -2 agonists	Corticosteroids
Anticholinergics	<u>Oxygen</u>
Anti IgE	<u>Mucoactive drugs</u>
	<u>Antibiotics</u>
	<u>Vaccines</u>

Table 9. DRUGS FOR ASTHMA AND COPD

bronchodilator response, who have notes about allergic or inflammatory response, repeated exacerbations or variable course of illness and in advanced COPD (24, 45, 49-54). **The treatment with combined therapy: LABA/ICS** (long-acting  $\beta$ -2 agonists/ inhalatory corticosteroids) is effective in **both:** asthma and COPD (46-48, 50, 52-54) which suggests that these two diseases have some similar patophysiologic characteristics. In **both** asthma and COPD early treatment can influence on: morbidity and mortality -reduced, quality of life –improved, costs of treatment –reduced (1, 24, 45-48, 50, 52-54). According to the course of illness it is unknown in asthma, but in COPD only the cut off smoking can have a positive influence (24). There is no therapy that can fully modify: re-modulation of small airways in asthma, and re-modulation of small airways, loss of alveolar connections, and collagen/ elastin destruction in COPD (1, 24).

**5. CONCLUSION**

Bronchial asthma and COPD are obstructive pulmonary diseases that affected millions of people all over the world. Although asthma and COPD have many differences they also have some similarities. They are two different diseases with differences in etiology, symptoms, type of airway inflammation, inflammatory cells, mediators, consequences of inflammation, response to therapy, course. Some similarities in airway inflammation in severe asthma and COPD and good response to combined therapy (LABA/ ICS) in both these diseases suggest that they have similar patophysiologic characteristics. Today asthma and COPD are not fully curable, not identified enough and not treated enough and the therapy is still developing. But in future better understanding of pathology, adequate identifying and treatment, perhaps and new drugs will provide a much better quality of life, reduced morbidity and mortality of these patients.

**REFERENCES:**

1. GINA (Global Initiative for Asthma) – global strategy for asthma management and prevention, revised 2006. Http// www.ginasthma.

- org.: 1-92.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy*. 2004; 59(5): 469-478.
  3. Beasley R. The Global Burden of Asthma Report, Global Initiative for Asthma (GINA). Available from <http://www.ginasthma.org> 2004.
  4. Holgate ST. Genetic and environmental interaction in allergy and asthma. *J Allergy Clin Immunol*. 1999; 104(6):1139-1146.
  5. Holloway JW, Beghe B, Holgate ST. The genetic basis of atopic asthma. *Clin Exp Allergy*. 1999; 29(8):1023-1032.
  6. Wiesch DG, Meyers DA, Bleecker ER. Genetics of asthma. *J Allergy Clin Immunol*. 1999; 104(5):895-901.
  7. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? *J Allergy Clin Immunol*. 2004; 114 (1): 58-65.
  8. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. *Trends Immunol*. 2004; 25(9):477-482.
  9. Larche M, Robinson DS, Kay A B. The role of T lymphocytes in the pathogenesis of asthma. *J Allergy Clin Immunol*. 2003; 111(3): 450-463.
  10. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, Kronenberg M, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. *N Engl J Med*. 2006; 354(11): 1117-1129.
  11. Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma. *Curr Opin Immunol*. 2004; 16(6):702-708.
  12. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. *Am J Respir Cell Mol Biol*. 2004; 31(1): 3-7.
  13. Wenzel S. Mechanisms of severe asthma. *Clin Exp Allergy*. 2003; 33(12):1622-1628.
  14. Chung KF. Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation? *Eur Respir J* 2000; 15(5): 961-968.
  15. Groneberg DA, Quarcoo D, Frossard N, Fischer A. Neurogenic mechanisms in bronchial inflammatory diseases. *Allergy*. 2004; 59(11): 1139-1152.
  16. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. *Pharmacol Rev*. 1998; 50(4): 515-596.
  17. Miller AL, Lukacs NW. Chemokine receptors: understanding their role in asthmatic disease. *Immunol Allergy Clin North Am*. 2004; 24(4): 667-683.
  18. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. *Annu Med Rev*. 2001; 52: 1-14
  19. Barnes PJ. Cytokine modulators as novel therapies for asthma. *Annu Rev Pharmacol Toxicol*. 2002; 42: 81-98.
  20. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. *Physiol Rev*. 2004; 84(3): 731-765.
  21. Smith AD, Taylor DR. Is exhaled nitric oxide measurement a useful clinical test in asthma? *Curr Opin Allergy Clin Immunol*. 2005; 5(1): 49-56.
  22. James A. Airway remodeling in asthma. *Curr Opin Pulm Med*. 2005; 11(1): 1-6.
  23. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al. Airway remodeling in asthma. *Chest*. 2003; 123(3 Suppl): 417S-422S.
  24. GOLD (Global Initiative for Chronic Obstructive Lung Disease) - global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2006. [http:// www. goldcopd.org](http://www.goldcopd.org).: 1-100
  25. World Health Report. Geneva: World Health Organization. Available from URL: <http://www.who.int/whr/2000/en/statistics.htm>; 2000.
  26. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. *Eur Respir J*. 2006; 27(2): 397-412.
  27. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest*. 2005; 128(4): 2099-2107.
  28. Agusti AG. Systemic effects of chronic obstructive pulmonary disease. *Proc Am Thorac Soc*. 2005; 2(4): 367-370.
  29. Van Weel C, Schellevis FG. Comorbidity and guidelines: conflicting interests. *Lancet*. 2006; 367(9510): 550-551.
  30. Eisner MD, Balmes J, Katz BP, Trupin L, Yelin E, Blanc P. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. *Environ Health Perspect*. 2005; 4: 7-15.
  31. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. *Eur Respir J*. 2003; 22(4): 672-688.
  32. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. *Lancet*. 2004; 364(9435): 709-721.
  33. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2001; 163(6): 1304-1309.
  34. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. *N Engl J Med*. 2004; 350(26):2645-2653.
  35. Cosio MG, Majo J. Inflammation of the airways and lung parenchyma in COPD: role of T cells. *Chest*. 2002; 121(5 Suppl):160S-165S.
  36. Barnes PJ. Macrophages as orchestrators of COPD. *J COPD*. 2004; 1: 59-70.
  37. Barnes PJ. Mediators of chronic obstructive pulmonary disease. *Pharmacol Rev*. 2004; 56(4): 515-548.
  38. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. *Allergy*. 2005; 60(1): 23-29.
  39. Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. *Eur Respir J*. 2004; 24(1): 122-128
  40. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. *Eur Respir J*. 2005; 26(5): 948-968.
  41. Standardization of Spirometry, 1994. Update. American Thoracic Society. *Am J Respir Crit Care Med*. 1995; 152(3): 1107-1136.
  42. Standardized lung function testing. Official statement of the European Respiratory Society. *Eur Respir J Suppl*. 1993; 16: 1-100.
  43. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. *J Allergy Clin Immunol*. 1998; 102(4 Pt 1): 531-538.
  44. Kamada AK, Szeffler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, et al. Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network. *Am J Respir Crit Care Med*. 1996; 153(6 Pt 1): 1739-1748.
  45. Newman SP. Inhaler treatment options in COPD. *Eur Respir Rev*. 2005; 14(96): 102-108.
  46. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute. National Institutes of Health, 1997.
  47. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. *JAMA*. 2001; 285(20): 2583-2593.
  48. Hondras MA, Linde K, Jones AP. Manual therapy for asthma. *Cochrane Database Syst Rev*. 2005(2): CD001002.
  49. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. *Thorax*. 2003; 58(8): 654-658.
  50. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. *Thorax*. 2003; 58(8): 659-664.
  51. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*. 2000; 320(7245): 1297-1303.
  52. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. *Thorax*. 2005; 60(4): 301-304.
  53. Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW, et al. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. *Am Rev Respir Dis*. 1987; 135(5): 1069-1074.
  54. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. *Lancet*. 2003; 361(9356): 449-456.